Aurobindo Pharma has announced that its wholly-owned step-down subsidiary CuraTeQ Biologics s.r.o. has obtained marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Zefylti, its filgrastim biosimilar version.

Earlier in February 2025, Zefylti received the marketing authorisation in the European Union from the European Commission (EC). This is CuraTeQ’s second biosimilar to be approved by MHRA after the approval of Bevqolva in December 2024.

In December, the company announced that it had received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for Zefylti, intended for the treatment of neutropenia and the mobilisation of peripheral blood progenitor cells (PBPCs).